ストックスクリーナーアプリを入手
15.22
4.93%
-0.79
アフターアワーズ：
15.10
-0.12
-0.79%
前日終値:
$16.01
開ける：
$15.89
24時間の取引高:
1.52M
Relative Volume:
2.52
時価総額：
$818.97M
収益：
$217.25M
当期純損益:
$-50.92M
株価収益率:
-10.72
EPS:
-1.42
ネットキャッシュフロー:
$-100.85M
1週間 パフォーマンス:
+19.00%
1か月 パフォーマンス:
+5.69%
6か月 パフォーマンス:
-22.58%
1年 パフォーマンス:
-58.78%
1日の値動き範囲:
$15.10
$16.42
1週間の範囲:
$11.70
$17.66
52週間の値動き範囲:
$11.70
$41.55
Prothena Corporation Plc Stock (PRTA) Company Profile
名前
Prothena Corporation Plc
セクター
電話
011-353-1-236-2500
住所
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
PRTA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
15.22 | 818.97M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-04-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-27 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-11-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-06-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Oppenheimer | Outperform |
| 2021-05-26 | 開始されました | Citigroup | Buy |
| 2021-02-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-05-21 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-04-23 | ダウングレード | Jefferies | Buy → Hold |
| 2018-04-05 | 繰り返されました | Barclays | Overweight |
| 2017-11-20 | ダウングレード | Wedbush | Outperform → Neutral |
| 2017-09-29 | 繰り返されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Jefferies | Buy |
| 2017-04-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-12-21 | 開始されました | SunTrust | Buy |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-08-04 | 繰り返されました | Barclays | Overweight |
| 2016-05-13 | 開始されました | Barclays | Overweight |
| 2016-02-19 | 繰り返されました | Wedbush | Outperform |
| 2016-01-21 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Prothena Corporation Plc (PRTA) 最新ニュース
HC Wainwright Reiterates "Buy" Rating for Prothena (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Now Covered by Chardan Capital - MarketBeat
Demystifying Prothena Corp: Insights From 6 Analyst Reviews - Benzinga
Even after rising 16% this past week, Prothena (NASDAQ:PRTA) shareholders are still down 67% over the past three years - Simply Wall St
Prothena Corp (NASDAQ:PRTA) Stock Quotes, Forecast and News Summary - Benzinga
Prothena Shares Surge 43% Despite Setback in Parkinson's Drug Trial, Investors Eye Future Potential - mediahousepress
Prothena stock soars despite study miss By Investing.com - Investing.com Canada
Prothena stock soars despite study miss - Investing.com
Bank of America Lowers Prothena (NASDAQ:PRTA) Price Target to $22.00 - MarketBeat
Why Is Prothena Corp Stock Soaring Today?Roche Holding (OTC:RHHBY) - Benzinga
Prothena shares price target cut after Parkinson's study miss By Investing.com - Investing.com UK
Prothena stock gains despite Parkinson’s setback (RHHBY:OTCQX) - Seeking Alpha
Prothena (NASDAQ:PRTA) Hits New 52-Week LowHere's Why - MarketBeat
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease - Business Wire
Prothena (NASDAQ:PRTA) Stock Price Down 3.6%Time to Sell? - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Up 7.8%What's Next? - MarketBeat
Where are the Opportunities in (PRTA) - Stock Traders Daily
Prothena's SWOT analysis: biotech stock's high-risk, high-reward pipeline - Investing.com
Oppenheimer bullish on Prothena stock, sees $1B opportunity for birtamimab in rare disease - Investing.com UK
Janus Henderson Group PLC Sells 1,008,511 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Reaches New 1-Year LowWhat's Next? - MarketBeat
Charles Schwab Investment Management Inc. Decreases Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? - Yahoo Finance
Wellington Management Group LLP Has $69.91 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
FY2024 EPS Estimates for Prothena Increased by Analyst - MarketBeat
Systematic Financial Management LP Sells 185,638 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
FY2024 EPS Estimates for Prothena Raised by Zacks Research - Defense World
Prothena's SWOT analysis: high-risk pipeline stock faces crucial readouts - Investing.com India
Prothena's SWOT analysis: high-risk pipeline stock faces crucial readouts By Investing.com - Investing.com South Africa
Learn to Evaluate (PRTA) using the Charts - Stock Traders Daily
Prothena (NASDAQ:PRTA) Rating Lowered to “Sell” at StockNews.com - Defense World
Prothena FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Prothena FY2024 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
FY2024 EPS Estimates for Prothena Reduced by HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Hits New 12-Month LowHere's What Happened - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average PT from Brokerages - Defense World
FY2028 EPS Estimates for Prothena Increased by HC Wainwright - MarketBeat
Prothena's SWOT analysis: stock poised for potential breakthroughs amid risks - Investing.com India
Expert Ratings For Prothena Corp - Benzinga
Prothena's (PRTA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus - Yahoo Finance
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Prothena: Q3 Earnings Snapshot - Marketscreener.com
Prothena Corp PLC Reports Q3 2024 EPS Loss of $1.10, Beats Estimate; Revenue Misses at $1.0 Million - GuruFocus.com
Prothena Reports $59M Q3 Loss, Pipeline Updates Signal Key Trial Results in 2024-25 | PRTA Stock News - StockTitan
Prothena Corporation plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Prothena Co. plc (NASDAQ:PRTA) Receives $61.86 Average Target Price from Brokerages - MarketBeat
Prothena Corporation Plc (PRTA) 財務データ
収益
当期純利益
現金流量
EPS
Prothena Corporation Plc (PRTA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Walker Karin L | Chief Accounting Officer |
Jan 24 '24 |
Sale |
34.00 |
5,000 |
170,000 |
0 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):